Jefferies Financial Group began coverage on shares of City Therapeutics (NASDAQ:CTY – Free Report) in a report released on Monday morning,Zacks reports. The brokerage issued a strong-buy rating on the stock.
A number of other equities research analysts have also commented on the stock. Wall Street Zen upgraded shares of City Therapeutics to a “hold” rating in a report on Saturday, October 24th. Stifel Nicolaus initiated coverage on shares of City Therapeutics in a research report on Tuesday, November 10th. They set a “buy” rating and a $34.00 price target for the company. Zacks Research started coverage on shares of City Therapeutics in a report on Wednesday, November 11th. They issued a “hold” rating on the stock. Finally, Oppenheimer initiated coverage on shares of City Therapeutics in a research report on Tuesday, November 10th. They issued an “outperform” rating and a $46.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $37.33.
Get Our Latest Stock Analysis on City Therapeutics
City Therapeutics Price Performance
NASDAQ:CTY opened at $16.98 on Monday. City Therapeutics has a fifty-two week low of $15.81 and a fifty-two week high of $23.88.
Insider Buying and Selling
In other City Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the company’s stock in a transaction on Monday, October 19th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the acquisition, the insider owned 13,692,507 shares in the company, valued at $246,465,126. This represents a 1.26% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Robert Nelsen acquired 170,000 shares of the company’s stock in a transaction on Monday, October 19th. The stock was acquired at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. The disclosure for this purchase is available in the SEC filing.
City Therapeutics Company Profile
City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.
See Also
- Five stocks we like better than City Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
